Formulation and evaluation of liquisolid compacts of apixaban for anticoagulant activity

Abstract

The aim of this study was to investigate the potential of a liquisolid system to improve the dissolution rate and the bioavailability of Apixaban. Different methods such as, crystal engineering, solid dispersion, ball milling, complexation, and self-emulsifying drug delivery systems have all been used in recent research to increase the solubility of the drug, however the liquisolid compact has demonstrated better results for increasing dissolution. 23 full factorial design was used to optimize the formulation in which the carrier/coating material ratio were selected as independent variables. From the eight batches of liquisolid tablets developed, the formulation with PEG 400 non-volatile vehicle at a level of 50% w/w has the best disintegration time, acceptable dissolution profile, and superior flow qualities. Comparing the optimized formulation (A7) to a pure apixaban medication, pure drug formulation, a greater dissolving rate was observed. The liquisolid technique acts to be a promising approach for increasing the dissolution of poorly soluble drugs like apixaban.